Citation Impact
Citing Papers
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Myeloid-derived suppressor cells coming of age
2018 Standout
Anti-inflammatory activity of natural dietary flavonoids
2010 Standout
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
2016
Macrophages in immunoregulation and therapeutics
2023 Standout
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Anti-inflammatory Agents: Present and Future
2010
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
2015
Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation
2007
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
2009
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Proteasome Inhibitors with Photocontrolled Activity
2014 StandoutNobel
Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy
2020 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Therapeutic Targeting of the Tumor Microenvironment
2021
Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
2007
Three Decades of β-Lactamase Inhibitors
2010 Standout
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
2014
Natural product and natural product derived drugs in clinical trials
2014 Standout
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
2017
Works of Alessandra Larocca being referenced
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
2013
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
2020
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia
2004
Lenalidomide and its role in the management of multiple myeloma
2008
Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation.
2006
A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide
2011
The impact of response on bone-directed therapy in patients with multiple myeloma
2013
Current Treatment Strategies with Lenalidomide in Multiple Myeloma and Future Perspectives
2012
Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
2008